We are thrilled to announce that the U.S. FDA has cleared our IND application and granted Fast Track designation for our investigational combination therapy, tobevibart and elebsiran, for the treatment of chronic #hepatitis delta infection. Learn more here: https://bit.ly/4eFyNx5 #hepatitisdelta #hepatitisD #hepD
Vir Biotechnology, Inc.
Biotechnology Research
San Francisco, California 31,288 followers
Powering the Immune System to Transform Lives
About us
Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
- Website
-
http://www.vir.bio
External link for Vir Biotechnology, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Francisco, California
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
Get directions
1800 Owens St
Suite 900
San Francisco, California 94158, US
-
Get directions
Via Mirasole 1
Bellinzona, Ticino 6500, CH
Employees at Vir Biotechnology, Inc.
Updates
-
This #PrideMonth we’re proud to elevate the voices within our LGBTQIA community. At Vir, we believe it’s vital to cultivate an environment that fosters our virtue of authenticity. We celebrate our employees’ ability to be genuine, be open, and be themselves! #VirPride #Pride2024
-
At Vir, we believe that true innovation comes from diversity of thought and experiences. #Juneteenth serves as a poignant reflection of our commitment to fostering a culture that embraces and uplifts all communities. Together, let's make strides toward lasting change. #DiversityAndInclusion
-
Vir Biotechnology, Inc. reposted this
Chief Technology Officer (CTO), EVP Technical Operations & Quality at Vir Biotechnology & NIBRT Board member.
I’m looking forward to participating on a panel discussion this week on “Getting to Regulatory Approval” at the @Longwood Healthcare Leaders Spring MIT forum. This meeting is Co-hosted by Professors Phil Sharp and Bob Langer and held at MIT’s Koch Institute, June 17-18, and includes a broad spectrum of topics affecting the biopharma ecosystem. @longwoodhealthcareleaders @longwoodfund #longwoodhealthcareleaders #virbio
-
-
#ICYMI: The excitement about our preliminary #hepatitisdelta data continues as Vir CEO Marianne D. De Backer, MSc, PhD, MBA participated in a fireside chat during the goldmansachs 45th Annual Global Healthcare Conference. Listen to the recording to hear about our recent data and the expected company milestones ahead: https://bit.ly/4epvCt8 (registration required)
-
-
We were truly inspired by our time at #EASLCongress and by all the professionals we met. Here are some of our favorite photos from the event. To learn more about our work developing transformative treatments for #hepatitisdelta, please click here: https://bit.ly/3XDNr23 DR. SVEN FRANCQUE Marianne D. De Backer, MSc, PhD, MBA Jennifer Towne Carey Hwang, MD, PhD Mark Eisner Nancy Reau
-
-
The excitement surrounding our latest #hepatitisdelta data at #EASLCongress 2024 was inspiring. We asked three of our leaders to share their favorite moments from the event—watch their answers, then take a deep dive into our work here: https://bit.ly/3XDNr23 @EASLNews
-
We’re thrilled to be featured on the Nasdaq Tower display in Times Square in celebration of our recently announced preliminary Phase 2 clinical trial data on a potential treatment for #hepatitisdelta: https://bit.ly/4aR3rk7 #EASLCongress #hepatitisD EASL | The Home of Hepatology
-
-
We recently welcomed Dr. Mark Eisner to Vir as our new EVP and Chief Medical Officer. To get to know him better, we asked Mark five questions about his hobbies and his work. Read his answers here!
-
We’re excited to welcome Ramy Farid, Ph.D., and Norbert Bischofberger, Ph.D. to our board of directors. Their tremendous expertise and strategic insights will be invaluable as we work towards our mission of powering the immune system to transform lives. Learn more about them at these links: https://lnkd.in/gYVgPkP7 (Ramy) https://lnkd.in/gyT62qhj (Norbert)
-